KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sarepta Therapeutics (SRPT) Change in Intangibles: 2011-2025

Historic Change in Intangibles for Sarepta Therapeutics (SRPT) over the last 9 years, with Sep 2025 value amounting to $5.3 million.

  • Sarepta Therapeutics' Change in Intangibles was N/A to $5.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $17.7 million, marking a year-over-year change of. This contributed to the annual value of $10.0 million for FY2024, which is 90.20% down from last year.
  • Per Sarepta Therapeutics' latest filing, its Change in Intangibles stood at $5.3 million for Q3 2025, which was up 2,725.53% from $188,000 recorded in Q2 2025.
  • In the past 5 years, Sarepta Therapeutics' Change in Intangibles registered a high of $101.9 million during Q2 2023, and its lowest value of $94,000 during Q1 2023.
  • Moreover, its 3-year median value for Change in Intangibles was $3.8 million (2025), whereas its average is $20.0 million.
  • Per our database at Business Quant, Sarepta Therapeutics' Change in Intangibles skyrocketed by 10,538.30% in 2024 and then tumbled by 77.62% in 2025.
  • Over the past 4 years, Sarepta Therapeutics' Change in Intangibles (Quarterly) stood at $202,000 in 2022, then reached $101.9 million in 2023, then skyrocketed by 10,538.30% to $10.0 million in 2024, then plummeted by 77.62% to $5.3 million in 2025.
  • Its last three reported values are $5.3 million in Q3 2025, $188,000 for Q2 2025, and $2.2 million during Q1 2025.